Advaxis, Inc. (OTCQB:ADXS) (“Advaxis” or the “Company”), a leader in
developing the next generation of immunotherapies for cancer and
infectious diseases, announced that three abstracts describing research
with Advaxis Lm-LLO immunotherapies have been selected for poster
presentation at the Society for Immunotherapy of Cancer (SITC) 28th
Annual Meeting, November 8-10, 2013 at the Gaylord National Hotel &
Convention Center in National Harbor, MD.
The abstract titled “Listeria monocytogenes (Lm)-LLO
immunotherapies reduce the immunosuppressive activity of myeloid-derived
suppressor cells and regulatory T cells in the tumor microenvironment”
has been selected for oral presentation during the session, “Tumor
Microenvironment and Innate Cells Recognition" on November 8, 2013 from
9:40 AM to 12:00 PM. Anu Wallecha, Ph.D., Director of Research and
Development at Advaxis, will report on the localized effects of Lm-LLO
immunotherapies on the tumor microenvironment in preclinical studies
using transplantable mouse models.
The abstract titled “ADXS11-001 immunotherapy targeting HPV-E7: Updated
survival and safety data from a Phase 2 study in Indian women with
recurrent/refractory cervical cancer” has been selected for poster
presentation during the Vaccine session. Robert Petit, Ph.D., Chief
Scientific Officer of Advaxis, will present final 18-month survival and
updated safety data from the ongoing trial.
The abstract titled “Biomarker identification in serum samples from
patients with recurrent cervical cancer treated with ADXS11-001
immunotherapy” has been selected for poster presentation during the
session “Biomarkers and Immunoscoring”. Poonam Molli, Ph.D., Senior
Scientist at Advaxis, will report on the correlation of changes in
cytokine and chemokine levels pre- and post-dosing with ADXS11-001 from
the Phase 2 study in Indian women with recurrent/refractory cervical
cancer.
“The three presentations of Advaxis data at SITC reflect our growing
understanding of the unique attributes of the Advaxis platform
technology for immunotherapies. Dr. Wallecha’s presentation will
highlight the ability of Lm-LLO immunotherapy to counteract
immune suppressor cells that enable persistence of the tumor. We will
report final 18-month survival and final tumor response data from our
110 patient Phase 2 study in India in women with recurrent cervical
cancer. Dr. Molli’s presentation will illustrate the remarkable immune
stimulation that occurs in patients after treatment with ADXS11-001.
Together, these data paint a picture of an immunotherapy that has a
strong positive impact on the immune system while at the same time
counteracting immune suppression in the tumor microenvironment that can
lead to apparent prolonged survival and objective tumor responses from a
single immunotherapeutic agent,” commented Dr. Petit.
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing the next
generation of immunotherapies for cancer and infectious diseases.
Advaxis immunotherapies are based on a novel platform technology using
live, attenuated bacteria that are bio-engineered to secrete an
antigen/adjuvant fusion protein(s) that is designed to redirect the
powerful immune response all human beings have to the bacterium to
the cancer itself.
ADXS-HPV is currently being evaluated in four clinical trials for human
papillomavirus (HPV)-associated cancers: recurrent/refractory cervical
cancer (India), locally advanced cervical cancer (GOG/NCI U.S. study,
Clinical Trials.gov Identifier NCT01266460), head & neck cancer
(CRUK study, Clinical Trials.gov Identifier NCT01598792), and anal
cancer (BrUOG study, Clinical Trials.gov Identifier NCT01671488).
Advaxis has over 15 distinct immunotherapies in various stages of
development, developed directly by Advaxis and through strategic
collaborations with recognized centers of excellence such as: the National
Cancer Institute, Cancer
Research – UK, the University
of Pennsylvania, the Georgia
Regent University Cancer Center, the Karolinska
Institutet, and others.
For more information please visit: http://www.advaxis.com
Forward-Looking Statements
This news release contains forward-looking statements, including,
but not limited to: statements regarding the ability of ADXS-HPV to lead
to apparent prolonged survival and objective tumor responses from a
single immunotherapeutic agent. These forward-looking statements are
subject to a number of risks, including the risk factors set forth from
time to time in Advaxis' SEC filings, including but not limited to its
report on Form 10-K for the fiscal year ended October 31, 2012, which is
available at http://www.sec.gov.
The Company undertakes no obligation to publicly release the result of
any revision to these forward-looking statements, which may be made to
reflect the events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events, except as required by law. You
are cautioned not to place undue reliance on any forward-looking
statements.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20130903005542r1&sid=ntxv4&distro=nx)
Copyright Business Wire 2013